MorphoSys AG (XSWX:MOR) EBITDA Margin % : 93.33% (As of Dec. 2023)

View and export this data going back to 1999. Start your Free Trial

What is MorphoSys AG EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. MorphoSys AG's EBITDA for the three months ended in Dec. 2023 was CHF52.0 Mil. MorphoSys AG's Revenue for the three months ended in Dec. 2023 was CHF55.7 Mil. Therefore, MorphoSys AG's EBITDA margin for the quarter that ended in Dec. 2023 was 93.33%.

MorphoSys AG EBITDA Margin % Historical Data

The historical data trend for MorphoSys AG's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG EBITDA Margin % Chart

MorphoSys AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

Get a 7-Day Free Trial

-138.32

15.50

-286.81

51.96

-29.60

MorphoSys AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial															248.74	-21.51	-76.84	-81.50	93.33

Competitive Comparison of MorphoSys AG's EBITDA Margin %

For the Biotechnology subindustry, MorphoSys AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MorphoSys AG's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MorphoSys AG's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where MorphoSys AG's EBITDA Margin % falls into.

MorphoSys AG EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

MorphoSys AG's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-66.513	/	224.714
	=	-29.60 %

MorphoSys AG's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	51.997	/	55.715
	=	93.33 %

MorphoSys AG (XSWX:MOR) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

MorphoSys AG EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

MorphoSys AG (XSWX:MOR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (XSWX:MOR) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

MPSYF:USA MOR:USA 1MOR:Italy MORd:UK 0NDV:UK MOR:Germany MOR:Austria

Address

Semmelweisstrasse 7, Planegg, BY, DEU, 82152

Website

https://www.morphosys.com

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.